NCT06876636View on ClinicalTrials.gov

Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer

NAActive, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Breast Cancer Metastatic

Interventions

DRUG

Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T)

zoledronic acid + liposomal doxorubicin + cyclophosphamide followed by zoledronic acid + nab-paclitaxel Concurrent immunotherapy is permitted: pembrolizumab or toripalimab

Trial Locations (1)

710032

Xijing hospital, Xi'an

All Listed Sponsors

lead

Xijing Hospital

OTHER

NCT06876636 - Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer | Biotech Hunter | Biotech Hunter